Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.
तुलना करने के लिए मीट्रिक्स | 328130 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध328130पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −92.7x | −5.7x | −0.6x | |
PEG अनुपात | 2.67 | 0.01 | 0.00 | |
क़ीमत/बुक | 8.7x | 2.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 51.5x | 4.6x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | −17.5% | 160.6% | 53.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | −5.7% | 7.5% | अनलॉक करें |